Novel targets, better treatments Investor Presentation | June 2019 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the slides captioned "We go step by step on commercial" "Prolific late stage pipeline" "R&D ambition" "Filgotinib program" "FINCH summary up to w24" "Filgotinib: promising profile" "Inflammation market ~$65B by 2027" "$2.1B market with large unmet needs" "We are building a fibrosis port ...